Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2023-11-25 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (465 characters) and contains only a digital signature block with no substantive content, financial data, or report information. There is no indication of a full report, announcement, or detailed filing. Given the lack of content and the presence of a digital signature, this is likely an officer certification or attestation document. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-11-25 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is very short (1419 characters) and mentions that un-audited standalone and consolidated financial statements are published on a specific date in newspapers. There is no detailed financial data or analysis within the text itself, only a notice of publication. This fits the pattern of a Report Publication Announcement (RPA) rather than the actual financial report. The text does not contain officer certifications or regulatory attestations, so it is not a Regulatory Filing (RNS). Therefore, the document is best classified as a Report Publication Announcement (RPA).
2023-11-03 English
Publication of Unaudited Financial Results for the quarter and half year ended on 30th September 2023 in the newspapers.
Report Publication Announcement Classification · 95% confidence The document is very short (1419 characters) and primarily states that un-audited standalone and consolidated financial statements have been published on a specific date in newspapers. There is no detailed financial data or analysis within the text itself, only a notice of publication. This fits the pattern of a Report Publication Announcement (RPA), where the report is referenced as published elsewhere but not included in the document. Therefore, it should be classified as RPA rather than the actual financial report (like IR or 10-K).
2023-11-03 English
Unaudited financial results for the quarter and half year ended 30.09.2023
Regulatory Filings
2023-11-02 English
Financial Result Updates
Regulatory Filings
2023-11-02 English
Outcome of Board Meeting
Regulatory Filings
2023-11-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.